Physician profile
Robert Patrick Wills
NPI 1912369372
$8,310.00
in general payments reported to CMS, 2019-2025
18 companies · $6,571 in 2025
The $6,571 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $134 · 2021: $674 · 2022: $267 · 2023: $452 · 2025: $6,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $776 · Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $776.01 |
| Food and Beverage | $746.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,152.79 | 2021-2025 | Da Vinci Surgical System |
| Merit Medical Systems INC | $244.85 | 2023 | Aeromini Stent and Delivery System, Aero Stent and Delivery System |
| Astrazeneca Pharmaceuticals LP | $145.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.06 | 2019-2021 | |
| Pulmonx Corporation | $132.28 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.96 | 2021 | |
| Veran Medical Technologies, INC. | $115.50 | 2020 | |
| Olympus America INC. | $61.01 | 2025 | |
| Astellas Pharma US INC | $39.99 | 2019 | |
| Insmed, INC. | $35.42 | 2022 | |
| Kestra Medical Technology Services, INC. | $26.53 | 2025 | Assure Wcd |
| Glaxosmithkline, LLC. | $18.90 | 2022 | |
| Genzyme Corporation | $18.32 | 2020 | |
| Mylan Specialty L.P. | $15.79 | 2019 | |
| Boston Scientific Corporation | $12.32 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.51 | 2019 | |
| Merck Sharp & Dohme LLC | $11.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.